Spike Protein News and Research

RSS

Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe

Scientists from Germany have recently identified a new sub-lineage of the alpha variant of SARS-CoV-2 in some European countries.

4 Nov 2021

Cross-reactive immunity against coronaviruses

Researchers review the heterologous immunity to coronaviruses and the extent of immune cross-reactivity against SARS-CoV-2.

3 Nov 2021

Pre-clinical follow-up study boosting with original formulation and next generation INO-4802 SARS-CoV-2 vaccine candidate

Researchers describe the antibody-inducing effects of DNA-based synthetic vaccines INO-4800 and INO-4802 against SARS-CoV-2 in non-human primates.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines.

2 Nov 2021

The pros and cons of a COVID-19 vaccine booster

The authors provide an overview of current literature available to assess the need for COVID-19 vaccine booster doses and their potential target population.

2 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Trends in SARS-CoV-2 seroprevalence in Massachusetts

A new study reported findings from a retrospective, de-identified and systematic survey of SARS-CoV-2 seroprevalence among childbearing women in Massachusetts.

2 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Identification of common genes in COVID-19 and COPD

Based on protein-protein interactions, the paper shows the presence of ten genes that overlap between the two illnesses, also shared by several other deadly and debilitating diseases.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.

1 Nov 2021

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

The magnitude of cross-reactive antibodies correlated well with responses to the SARS-CoV-2 spike protein and the S2 subdomain.

1 Nov 2021

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

A cohort study found that antibodies to the SARS-CoV-2 spike protein and neutralizing antibodies remain relatively stable 8-11 months post-infection.

1 Nov 2021

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

1 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

A new study explores the role of new SARS-CoV-2 variants in sustaining the pandemic in South Africa.

31 Oct 2021

Study uncovers unknown effects of COVID-19 virus on the immune system

COVID-19 reduces the numbers and functional competence of certain types of immune cells in the blood, say LMU researchers. This could affect responses to secondary infections.

28 Oct 2021

Spike Protein News and Research

Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe

Cross-reactive immunity against coronaviruses

Pre-clinical follow-up study boosting with original formulation and next generation INO-4802 SARS-CoV-2 vaccine candidate

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

The pros and cons of a COVID-19 vaccine booster

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

Trends in SARS-CoV-2 seroprevalence in Massachusetts

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

Identification of common genes in COVID-19 and COPD

SARS-CoV-2 variants neutralized by camel nanobodies

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

Study uncovers unknown effects of COVID-19 virus on the immune system

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News